How to buy iHuman (IH.US) stock |

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy iHuman stock

Own iHuman stock in just a few minutes.

iHuman Inc is an education & training services business based in the US. iHuman shares (IH) are listed on the NYSE and all prices are listed in US Dollars. iHuman employs 437 staff and has a market cap (total outstanding shares value) of USD0.00.

How to buy shares in iHuman

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for iHuman. Find the stock by name or ticker symbol: IH. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until iHuman reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of iHuman, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of iHuman. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

iHuman share price

Use our graph to track the performance of IH stocks over time.

iHuman shares at a glance

Information last updated 2021-03-10.
52-week rangeUSD$12.12 - USD$30
50-day moving average USD$19.0279
200-day moving average USD$20.8745
Wall St. target priceUSD$16.05
PE ratio 24160.2
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.0008

Buy iHuman shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy iHuman stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is iHuman under- or over-valued?

Valuing iHuman stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of iHuman's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

iHuman's P/E ratio

iHuman's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24160x. In other words, iHuman shares trade at around 24160x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, iHuman's P/E ratio is best considered in relation to those of others within the education & training services industry or those of similar companies.

iHuman financials

Gross profit TTM USD$134.5 million
Return on assets TTM 0%
Return on equity TTM -9999999%
Profit margin 2.44%
Book value N/A
Market capitalisation USD$771 million

TTM: trailing 12 months

Shorting iHuman shares

There are currently 56,942 iHuman shares held short by investors – that's known as iHuman's "short interest". This figure is 68.7% up from 33,762 last month.

There are a few different ways that this level of interest in shorting iHuman shares can be evaluated.

iHuman's "short interest ratio" (SIR)

iHuman's "short interest ratio" (SIR) is the quantity of iHuman shares currently shorted divided by the average quantity of iHuman shares traded daily (recently around 116208.16326531). iHuman's SIR currently stands at 0.49. In other words for every 100,000 iHuman shares traded daily on the market, roughly 490 shares are currently held short.

To gain some more context, you can compare iHuman's short interest ratio against those of similar companies.

However iHuman's short interest can also be evaluated against the total number of iHuman shares, or, against the total number of tradable iHuman shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case iHuman's short interest could be expressed as 0% of the outstanding shares (for every 100,000 iHuman shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable iHuman shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against iHuman.

Find out more about how you can short iHuman stock.

iHuman share dividends

We're not expecting iHuman to pay a dividend over the next 12 months.

You may also wish to consider:

iHuman overview

iHuman Inc. provides childhood edutainment products and services to individual users, education organizations, and distributors in the People's Republic of China. The company offers interactive and self-directed learning apps, including iHuman Chinese, iHuman English World, iHuman Pinyin, iHuman Magic Math, iHuman Books, and iHuman Stories. It also provides learning materials in physical and digital formats; and smart learning devices. The company was founded in 1996 and is based in Beijing, the People's Republic of China. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site